Dramatic response to alectinib in a patient with ALK‐rearranged squamous cell lung cancer

Abstract Lung cancers with anaplastic lymphoma kinase (ALK) rearrangements are highly sensitive to treatment with ALK tyrosine kinase inhibitors (TKIs). Due to the very low rate of patients with squamous cell carcinoma enrolled in clinical trials, the efficacy of ALK inhibitors in patients with ALK‐...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jun Shiihara, Fumiyoshi Ohyanagi, Hikari Amari, Minemichi Toda, Hiroki Tahara, Motoi Yuzawa, Yuki Maeda, Motoko Nomura, Yoshiko Mizushina, Yoshiaki Nagai, Hiromitsu Ohta, Yasuhiro Yamaguchi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2021-09-01
Colecção:	Thoracic Cancer
Assuntos:	alectinib anaplastic lymphoma kinase lung cancer squamous cell cancer
Acesso em linha:	https://doi.org/10.1111/1759-7714.14092
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!